This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Interna Technologies B.v.. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Judith Rosina Van Beijnum - Innovator in miRNA Therapeutics
Introduction: Judith Rosina Van Beijnum is a noteworthy inventor based in Hilversum, Netherlands. She has made significant contributions to the field of biotechnology with her innovative patent in the realm of miRNA, which has crucial implications for treating diseases related to neo-angiogenesis.
Latest Patents: Judith holds a patent for "MiRNA for treating diseases and conditions associated with neo-angiogenesis." This invention focuses on the diagnostic and therapeutic applications of a miRNA molecule, or its equivalents, particularly regarding conditions linked to abnormal angiogenesis. Her pioneering work in this area opens new pathways for potential treatments and contributes to the advancement of medical science.
Career Highlights: Judith is currently associated with Interna Technologies B.V., where she applies her expertise in developing innovative biotechnological solutions. Her work reflects a commitment to improving healthcare through research and innovation, showcasing her role as a leading figure in her field.
Collaborations: Judith collaborates with talented professionals such as Sanne Weijzen and Roeland Quirinus Jozef Schaapveld. These partnerships enhance her research efforts and expand the impact of her inventions, underlining the importance of teamwork in scientific innovation.
Conclusion: Judith Rosina Van Beijnum's contributions through her patent signify a critical advancement in the understanding and treatment of diseases related to neo-angiogenesis. Her work at Interna Technologies B.V. and collaborations with esteemed colleagues highlight her influence in the biotechnology sector. She continues to be an inspiring figure in the landscape of innovation, demonstrating the potential of miRNA-based therapeutics in modern medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile